INDBInternet News Database 2.5 Updated 2 min ago · 367 sources Show or hide images Light or dark

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

Save Like Comments Compare coverage
Image from Reuters

Summary

(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody could soon... Covered by 5 outlets: 1 lean left, 3 are centre, 1 lean right.

Automated summary picked from the outlets' own descriptions.

Who is covering this

  1. ReasonTV Leans right Factuality: Mostly factual US
    China Approved This Lung Cancer Drug. The FDA Is Making Americans Wait.

    Red background with packaging for a Chinese lung cancer drug

  2. Ibtimes Center Factuality: Mostly factual GB
    FDA Rejects China's Cancer Drug as 'Blow to Beijing' Framing Unleashes Fury Over American Lung Cancer Patients

    The FDA rejected ivonescimab after its trial failed to show a statistically significant overall-survival benefit, despite delaying lung cancer progression in previously treated patients.

  3. Reuters Center Factuality: Very high GB
    US FDA approves Roche's oral treatment for advanced breast cancer - Reuters

    US FDA approves Roche's oral treatment for advanced breast cancer Reuters

  4. The Epoch Times Right Factuality: Low US
    FDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed

    The U.S. Food and Drug Administration in White Oak, Md., on June 5, 2023. (Madalina Vasiliu/The Epoch Times)

    Low reliability sourceElevated risk
  5. Medpagetoday Center Factuality: Mostly factual US
    FDA Rejects Promising Cancer Drug Developed in China

    (MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody could soon...

  6. Quartz Leans left Factuality: High US
    FDA declined to approve Summit Therapeutics' lung cancer drug

    The agency said ivonescimab lacks a statistically significant overall survival benefit; Summit said it will continue development

  7. Reuters Center Factuality: Very high GB
    US FDA declines to approve Summit lung cancer drug after trial misses key survival goal - Reuters

    US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters

Comments

Comments need JavaScript.